BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24980881)

  • 1. Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study.
    Verbeek RE; Leenders M; Ten Kate FJ; van Hillegersberg R; Vleggaar FP; van Baal JW; van Oijen MG; Siersema PD
    Am J Gastroenterol; 2014 Aug; 109(8):1215-22. PubMed ID: 24980881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
    Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
    Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
    Quera R; O'Sullivan K; Quigley EM
    Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.
    Sikkema M; Looman CW; Steyerberg EW; Kerkhof M; Kastelein F; van Dekken H; van Vuuren AJ; Bode WA; van der Valk H; Ouwendijk RJ; Giard R; Lesterhuis W; Heinhuis R; Klinkenberg EC; Meijer GA; ter Borg F; Arends JW; Kolkman JJ; van Baarlen J; de Vries RA; Mulder AH; van Tilburg AJ; Offerhaus GJ; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD
    Am J Gastroenterol; 2011 Jul; 106(7):1231-8. PubMed ID: 21577245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA).
    Rugge M; Zaninotto G; Parente P; Zanatta L; Cavallin F; Germanà B; Macrì E; Galliani E; Iuzzolino P; Ferrara F; Marin R; Nisi E; Iaderosa G; Deboni M; Bellumat A; Valiante F; Florea G; Della Libera D; Benini M; Bortesi L; Meggio A; Zorzi MG; Depretis G; Miori G; Morelli L; Cataudella G; d'Amore ES; Franceschetti I; Bozzola L; Paternello E; Antonini C; Di Mario F; Dal Bò N; Furlanetto A; Norberto L; Polese L; Iommarini S; Farinati F; Battaglia G; Diamantis G; Realdon S; Guido E; Mastropaolo G; Canova D; Guerini A; Franceschi M; Zirillo M
    Ann Surg; 2012 Nov; 256(5):788-94; discussion 794-5. PubMed ID: 23095623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus.
    Nguyen T; Thrift AP; Yu X; Duan Z; El-Serag HB
    Am J Gastroenterol; 2017 Jul; 112(7):1049-1055. PubMed ID: 28244499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
    Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
    United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival.
    Tramontano AC; Sheehan DF; Yeh JM; Kong CY; Dowling EC; Rubenstein JH; Abrams JA; Inadomi JM; Schrag D; Hur C
    Am J Gastroenterol; 2017 Aug; 112(8):1256-1264. PubMed ID: 28374815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma.
    Grant KS; DeMeester SR; Kreger V; Oh D; Hagen JA; Chandrasoma P; DeMeester TR
    J Thorac Cardiovasc Surg; 2013 Jul; 146(1):31-7. PubMed ID: 23312980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.
    Conio M; Blanchi S; Lapertosa G; Ferraris R; Sablich R; Marchi S; D'Onofrio V; Lacchin T; Iaquinto G; Missale G; Ravelli P; Cestari R; Benedetti G; Macrì G; Fiocca R; Munizzi F; Filiberti R
    Am J Gastroenterol; 2003 Sep; 98(9):1931-9. PubMed ID: 14499768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
    O'Connor JB; Falk GW; Richter JE
    Am J Gastroenterol; 1999 Aug; 94(8):2037-42. PubMed ID: 10445525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
    Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
    Provenzale D; Schmitt C; Wong JB
    Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of adenocarcinoma among patients with Barrett's esophagus.
    Hvid-Jensen F; Pedersen L; Drewes AM; Sørensen HT; Funch-Jensen P
    N Engl J Med; 2011 Oct; 365(15):1375-83. PubMed ID: 21995385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus.
    El-Serag HB; Naik AD; Duan Z; Shakhatreh M; Helm A; Pathak A; Hinojosa-Lindsey M; Hou J; Nguyen T; Chen J; Kramer JR
    Gut; 2016 Aug; 65(8):1252-60. PubMed ID: 26311716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
    Wong T; Tian J; Nagar AB
    Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.